Search
CCX915
go.drugbank.com/drugs/DB05159ExperimentalCCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.
Tedisamil
go.drugbank.com/drugs/DB06200ExperimentalIt is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.
Ephedra sinica root
go.drugbank.com/drugs/DB01363ApprovedNutraceuticalEphedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 d...
Aminolevulinic acid
go.drugbank.com/drugs/DB00855ApprovedInvestigationalA compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Lorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnIt has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.
Biperiden
go.drugbank.com/drugs/DB00810ApprovedInvestigationalWithdrawnIt has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
Botulinum toxin type B
go.drugbank.com/drugs/DB00042ApprovedNeurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex.
Vestronidase alfa
go.drugbank.com/drugs/DB12366ApprovedInvestigationalVestronidase alfa, or vestronidase alfa-vjbk, is a recombinant human lysosomal beta glucuronidase that is a purified enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. … In clinical trials, vestronidase alfa treatment demonstrated improvement and stabilization in motor symptoms by increasing the patients' ability to walk longer distances in comparison to treatment with
Leucovorin
go.drugbank.com/drugs/DB00650ApprovedInvestigational[L56092, A257419] Unlike folic acid, leucovorin does not require the enzyme dihydrofolate reductase (DHFR) for activation, allowing it to function even when DHFR is inhibited by drugs like methotrexate